Endo Pharmaceuticals Holdings Inc. (ENDP) said that its partners, Teikoku Seiyaku Co. Ltd. and Teikoku Pharma USA Inc. have received a Paragraph IV Certification Notice from Watson Laboratories Inc. (WPI) regarding the filing of an abbreviated new drug application for a generic version of Lidoderm.
Lidoderm is a topical patch to relieve the pain of postherpetic neuralgia launched in 1999. Its patent is listed in the FDA's Orange Book and expires in October 2015.
The company said it is currently reviewing the details of this notice from Watson. Endo intends to vigorously defend Lidoderm's intellectual property rights and pursue all available legal and regulatory pathways in defense of Lidoderm.
For comments and feedback: editorial@rttnews.com